{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Hypertension","Metastatic Colorectal Cancer","Metastatic Breast Cancer","Colorectal Neoplasms","Breast Neoplasms"],"disease":["Hypertension","Metastatic Colorectal Cancer","Metastatic Breast Cancer","Colorectal Neoplasms","Breast Neoplasms"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2135628"],"location":["Spain"],"study_start_month":["10"],"keyword":["Bevacizumab Response Predictors","Metastatic Colon Cancer"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer","description":"This is a multicenter, post-authorization observational with prospective follow-up (EPA-SP) study. Will be involved 137 metastatic breast cancer patients or metastatic colorectal cancer. The hypertension will be evaluated as a predictor of efficacy of bevacizumab associated with chemotherapy, in terms of progression-free survival (PFS) (Main endpoint).\nThe duration of the study will be approximately 42 months.","dates":{"creation":"2012-10-15"},"accession":"2135628","cross_references":{"ClinicalTrials___gov":["NCT01733628"]}}